Skip to main content
NCBI home page
Journal of Clinical Pathology logoLink to Journal of Clinical Pathology
. 1987 Oct;40(10):1182–1186. doi: 10.1136/jcp.40.10.1182

Oxpentifylline and cetiedil citrate improve deformability of dehydrated sickle cells.

J Stuart 1, P C Stone 1, Y Y Bilto 1, A J Keidan 1
PMCID: PMC1141191  PMID: 3119675

Abstract

Erythrocytes from 14 patients with homozygous sickle cell anaemia were treated with the calcium ionophore A23187 to induce loss of cellular potassium and water. The dehydrated cells showed a decrease in filterability (loss of deformability) through pores of 5 micron diameter. Oxpentifylline and cetiedil citrate, which preserve erythrocyte cation and water content, had a significant (p less than 0.01) protective effect against loss of deformability at a concentration of 1 mumol/l. Oxpentifylline showed no adverse effect on the rheology, morphology, or haemolysis of sickle cells at concentrations up to 500 mumol/l. Drugs that act on the erythrocyte membrane to maintain cell hydration are of potential rheological benefit in sickle cell anaemia.

Full text

PDF
1182

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agee J. F., Garver F. A., Faguet G. B. An antigen common to chronic lymphocytic and hairy cell leukemia cells not shared by normal lymphocytes or by other leukemic cells. Blood. 1986 Jul;68(1):62–68. [PubMed] [Google Scholar]
  2. Benjamin L. J., Berkowitz L. R., Orringer E., Mankad V. N., Prasad A. S., Lewkow L. M., Chillar R. K., Peterson C. M. A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis. Blood. 1986 May;67(5):1442–1447. [PubMed] [Google Scholar]
  3. Benjamin L. J., Kokkini G., Peterson C. M. Cetiedil: its potential usefulness in sickle cell disease. Blood. 1980 Feb;55(2):265–270. [PubMed] [Google Scholar]
  4. Berkowitz L. R., Orringer E. P. An analysis of the mechanism by which cetiedil inhibits the Gardos phenomenon. Am J Hematol. 1984 Oct;17(3):217–223. doi: 10.1002/ajh.2830170302. [DOI] [PubMed] [Google Scholar]
  5. Berkowitz L. R., Orringer E. P. Effect of cetiedil, an in vitro antisickling agent, on erythrocyte membrane cation permeability. J Clin Invest. 1981 Nov;68(5):1215–1220. doi: 10.1172/JCI110367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bessis M. Red cell shapes. An illustrated classification and its rationale. Nouv Rev Fr Hematol. 1972 Nov-Dec;12(6):721–745. [PubMed] [Google Scholar]
  7. Brugnara C., Bunn H. F., Tosteson D. C. Regulation of erythrocyte cation and water content in sickle cell anemia. Science. 1986 Apr 18;232(4748):388–390. doi: 10.1126/science.3961486. [DOI] [PubMed] [Google Scholar]
  8. Charache S., Walker W. G. Failure of desmopressin to lower serum sodium or prevent crisis in patients with sickle cell anemia. Blood. 1981 Nov;58(5):892–896. [PubMed] [Google Scholar]
  9. Clark M. R., Mohandas N., Embury S. H., Lubin B. H. A simple laboratory alternative to irreversibly sickled cell (ISC) counts. Blood. 1982 Sep;60(3):659–662. [PubMed] [Google Scholar]
  10. Clark M. R., Mohandas N., Shohet S. B. Deformability of oxygenated irreversibly sickled cells. J Clin Invest. 1980 Jan;65(1):189–196. doi: 10.1172/JCI109650. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Evans E., Mohandas N., Leung A. Static and dynamic rigidities of normal and sickle erythrocytes. Major influence of cell hemoglobin concentration. J Clin Invest. 1984 Feb;73(2):477–488. doi: 10.1172/JCI111234. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fabry M. E., Nagel R. L. The effect of deoxygenation on red cell density: significance for the pathophysiology of sickle cell anemia. Blood. 1982 Dec;60(6):1370–1377. [PubMed] [Google Scholar]
  13. GARDOS G. The role of calcium in the potassium permeability of human erythrocytes. Acta Physiol Acad Sci Hung. 1959;15(2):121–125. [PubMed] [Google Scholar]
  14. Glader B. E., Nathan D. G. Cation permeability alterations during sickling: relationship to cation composition and cellular hydration of irreversibly sickled cells. Blood. 1978 May;51(5):983–989. [PubMed] [Google Scholar]
  15. Gulley M. L., Ross D. W., Feo C., Orringer E. P. The effect of cell hydration on the deformability of normal and sickle erythrocytes. Am J Hematol. 1982 Dec;13(4):283–291. doi: 10.1002/ajh.2830130403. [DOI] [PubMed] [Google Scholar]
  16. Hofrichter J., Ross P. D., Eaton W. A. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. Proc Natl Acad Sci U S A. 1974 Dec;71(12):4864–4868. doi: 10.1073/pnas.71.12.4864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Keller F., Leonhardt H. Amelioration of blood viscosity in sickle cell anemia by pentoxifylline. A case report. J Med. 1979;10(6):429–433. [PubMed] [Google Scholar]
  18. Leary M., Abramson N. Induced hyponatremia for sickle-cell anemia. N Engl J Med. 1981 Apr 2;304(14):844–845. doi: 10.1056/NEJM198104023041414. [DOI] [PubMed] [Google Scholar]
  19. Masys D. R., Bromberg P. A., Balcerzak S. P. Red cells shrink during sickling. Blood. 1974 Dec;44(6):885–889. [PubMed] [Google Scholar]
  20. Mohandas N., Rossi M. E., Clark M. R. Association between morphologic distortion of sickle cells and deoxygenation-induced cation permeability increase. Blood. 1986 Aug;68(2):450–454. [PubMed] [Google Scholar]
  21. Noguchi C. T., Torchia D. A., Schechter A. N. Intracellular polymerization of sickle hemoglobin. Effects of cell heterogeneity. J Clin Invest. 1983 Sep;72(3):846–852. doi: 10.1172/JCI111055. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ohnishi S. T., Horiuchi K. Y., Horiuchi K., Jurman M. E., Sadanaga K. K. Nitrendipine, nifedipine and verapamil inhibit the in vitro formation of irreversibly sickled cells. Pharmacology. 1986;32(5):248–256. doi: 10.1159/000138177. [DOI] [PubMed] [Google Scholar]
  23. Orringer E. P., Powell J. R., Cross R. E., Rogers J. F., Wojcieszyn O., Phillips J. C., Reed J., Ng K. T., Berkowitz L. R. A single-dose pharmacokinetic study of the antisickling agent cetiedil. Clin Pharmacol Ther. 1986 Mar;39(3):276–281. doi: 10.1038/clpt.1986.39. [DOI] [PubMed] [Google Scholar]
  24. Porter J. M., Cutler B. S., Lee B. Y., Reich T., Reichle F. A., Scogin J. T., Strandness D. E. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J. 1982 Jul;104(1):66–72. doi: 10.1016/0002-8703(82)90642-1. [DOI] [PubMed] [Google Scholar]
  25. Reinhart W. H., Chien S. Roles of cell geometry and cellular viscosity in red cell passage through narrow pores. Am J Physiol. 1985 May;248(5 Pt 1):C473–C479. doi: 10.1152/ajpcell.1985.248.5.C473. [DOI] [PubMed] [Google Scholar]
  26. Richman C. M., Chess L., Yankee R. A. Purification and characterization of granulocytic progenitor cells (CFU-C) from human peripheral blood using immunologic surface markers. Blood. 1978 Jan;51(1):1–8. [PubMed] [Google Scholar]
  27. Schmidt W. F., 3rd, Asakura T., Schwartz E. Effect of cetiedil on cation and water movements in erythrocytes. J Clin Invest. 1982 Mar;69(3):589–594. doi: 10.1172/JCI110485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Schmidt W. F., Asakura T., Schwartz E. The effect of cetiedil on red cell membrane permeability. Blood Cells. 1982;8(2):289–298. [PubMed] [Google Scholar]
  29. Seiffge D., Berthold R., Berthold F. Effect of pentoxifylline on sickle cell thalassaemia: haemorheological and clinical results. Klin Wochenschr. 1983 Nov 15;61(22):1159–1160. doi: 10.1007/BF01530845. [DOI] [PubMed] [Google Scholar]
  30. Simaan J. A., Aviado D. M. A comparative study between the cardiovascular effects of cetiedil, a new vasodilator, and papaverine and aminophylline. J Pharmacol Exp Ther. 1976 Jul;198(1):176–186. [PubMed] [Google Scholar]

Articles from Journal of Clinical Pathology are provided here courtesy of BMJ Publishing Group

RESOURCES